Fiber-Optic system for dual-modality imaging of glucose probes 18F-FDG and 6-NBDG in atherosclerotic plaques

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Zaman, Raiyan T ^a   Kosuge, Hisanori ^a   Pratx, Guillem ^a   Carpenter, Colin ^a   Xing, Lei ^a   McConnell, Michael V ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (N (7 NITROBENZ 2 OXA 1,3 DIAZOL 4 YL )AMINO) 6 DEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GLUCOSE DERIVATIVE; UNCLASSIFIED DRUG; 4 CHLORO 7 NITROBENZOFURAZAN; 6-DEOXY-N-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)AMINOGLUCOSE; GLUCOSAMINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTORADIOGRAPHY; CAROTID ARTERY; CONTROLLED STUDY; EX VIVO STUDY; FEASIBILITY STUDY; FIBER OPTICS; FIBEROPTIC CATHETER; FLUORESCENCE IMAGING SYSTEM; IMAGE ANALYSIS; IMAGING SYSTEM; LEFT CAROTID ARTERY; MACROPHAGE; MALE; MOUSE; NONHUMAN; RIGHT CAROTID ARTERY; VALIDATION PROCESS; ANALOGS AND DERIVATIVES; ANIMAL; CAROTID ARTERY DISEASE; DIAGNOSTIC IMAGING; SCINTISCANNING;

4-CHLORO-7-NITROBENZOFURAZAN; ANIMALS; CAROTID ARTERY DISEASES; DIAGNOSTIC IMAGING; FIBER OPTIC TECHNOLOGY; FLUORODEOXYGLUCOSE F18; GLUCOSAMINE; MALE; MICE; PLAQUE, ATHEROSCLEROTIC; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 84907213549     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108108     Document Type: Article

References (38)

1. Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, et al. (2010) Community programs for the prevention of cardiovascular disease: a systematic review. Am J Epidemiol 172: 501-516.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127: e6-e245.
3. Waxman S, Ishibashi F, Muller JE (2006) Detection and treatment of vulnerable plaques and vulnerable patients -Novel approaches to prevention of coronary events. Circulation 114: 2390-2411.
4. Yamaguchi Y, Patt BE, Iwanczyk JS, MacDonald LM, Mari C, et al. (2004) Performance of intravascular probe in animal studies. 2003 Ieee Nuclear Science Symposium, Conference Record, Vols 1-5: 2463-2467.
5. Chen IY, Wu JC (2011) Cardiovascular molecular imaging: focus on clinical translation. Circulation 123: 425-443.
6. McLachlan SJ, Morris MR, Lucas MA, Fisco RA, Eakins MN, et al. (1994) Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 4: 301-307.
7. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, et al. (2009) The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxideenhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 53: 2039-2050.
8. Dimastromatteo J, Broisat A, Perret P, Ahmadi M, Boturyn D, et al. (2013) In Vivo Molecular Imaging of Atherosclerotic Lesions in ApoE2/2 Mice Using VCAM-1-Specific, 99mTc-Labeled Peptidic Sequences. J Nucl Med.
9. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, et al. (2007) Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 13: 636-641.
10. Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, et al. (2008) Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 118: 1802-1809.
11. Menezes LJ, Kayani I, Ben-Haim S, Hutton B, Ell PJ, et al. (2010) What is the natural history of 18F-FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque. Atherosclerosis 211: 136-140.
12. Menezes LJ, Kotze CW, Agu O, Richards T, Brookes J, et al. (2011) Investigating vulnerable atheroma using combined (18)F-FDG PET/CT angiography of carotid plaque with immunohistochemical validation. J Nucl Med 52: 1698-1703.
13. Ogawa M, Nakamura S, Saito Y, Kosugi M, Magata Y (2012) What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro. J Nucl Med 53: 55-58.
14. Gaeta C, Fernandez Y, Pavia J, Flotats A, Artigas C, et al. (2011) Reduced myocardial 18F-FDG uptake after calcium channel blocker administration. Initial observation for a potential new method to improve plaque detection. Eur J Nucl Med Mol Imaging 38: 2018-2024.
15. Yoo H, Kim JW, Shishkov M, Namati E, Morse T, et al. (2011) Intra-Arterial catheter for simultaneous microstructural and molecular imaging in vivo. Nat Med 17: 1680-1684.
16. ONeil RG, Wu L, Mullani N (2005) Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. Mol Imaging Biol 7: 388-392.
17. Jung DW, Ha HH, Zheng X, Chang YT, Williams DR (2011) Novel use of fluorescent glucose analogues to identify a new class of triazine-based insulin mimetics possessing useful secondary effects. Mol Biosyst 7: 346-358.
18. Yoshioka K, Takahashi H, Homma T, Saito M, Oh KB, et al. (1996) A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli. Biochim Biophys Acta 1289: 5-9.
19. Zhang Z, Machac J, Helft G, Worthley SG, Tang C, et al. (2006) Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med 6: 3.
20. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, et al. (2008) Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117: 379-387.
21. Barros LF, Bittner CX, Loaiza A, Ruminot I, Larenas V, et al. (2009) Kinetic validation of 6-NBDG as a probe for the glucose transporter GLUT1 in astrocytes. J Neurochem 109 Suppl 1: 94-100.
22. Weber MJ (2004) Scintillation: mechanisms and new crystals. Nuclear Instruments & Methods in Physics Research Section a-Accelerators Spectrometers Detectors and Associated Equipment 527: 9-14.
23. Shikhaliev PM, Xu T, Ducote JL, Easwaramoorthy B, Mukherjee J, et al. (2006) Positron autoradiography for intravascular imaging: feasibility evaluation. Phys Med Biol 51: 963-979.
24. Cherry SR, Sorenson JA, Phelps ME (2003) Physics in nuclear medicine. Philadelphia, PA: Saunders.
25. Kosuge H, Sherlock SP, Kitagawa T, Dash R, Robinson JT, et al. (2012) Near infrared imaging and photothermal ablation of vascular inflammation using single-walled carbon nanotubes. J Am Heart Assoc 1: e002568.
26. Terashima M, Uchida M, Kosuge H, Tsao PS, Young MJ, et al. (2011) Human ferritin cages for imaging vascular macrophages. Biomaterials 32: 1430-1437.
27. Kosuge H, Sherlock SP, Kitagawa T, Terashima M, Barral JK, et al. (2011) FeCo/Graphite Nanocrystals for Multi-Modality Imaging of Experimental Vascular Inflammation. Plos One 6.
28. Uchida M, Kosuge H, Terashima M, Willits DA, Liepold LO, et al. (2011) Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano 5: 2493-2502.
29. Funk T, Sun M, Hasegawa BH (2004) Radiation dose estimate in small animal SPECT and PET. Medical Physics 31: 2680.
30. Stabin MG, Tagesson M, Thomas SR, Ljungberg M, Strand SE (1999) Radiation dosimetry in nuclear medicine. Applied Radiation and Isotopes 50: 73-87.
31. Calfon MA, Vinegoni C, Ntziachristos V, Jaffer FA (2010) Intravascular nearinfrared fluorescence molecular imaging of atherosclerosis: toward coronary arterial visualization of biologically high-risk plaques. J Biomed Opt 15: 011107.
32. Inglese E, Leva L, Matheoud R, Sacchetti G, Secco C, et al. (2007) Spatial and Temporal Heterogeneity of Regional Myocardial Uptake in Patients Without Heart Disease Under Fasting Conditions on Repeated Whole-Body 18F-FDG PET/CT. Journal of Nuclear Medicine 48: 1662-1669.
33. Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, et al. (2010) Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging 3: 388-397.
34. Tahara N, Mukherjee J, de Haas HJ, Petrov AD, Tawakol A, et al. (2014) 2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis. Nat Med 20: 215-219.
35. Jaffer FA, Libby P, Weissleder R (2007) Molecular imaging of cardiovascular disease. Circulation 116: 1052-1061.
36. Jaffer FA, Libby P, Weissleder R (2009) Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1017-1024.
37. Speizer L, Haugland R, Kutchai H (1985) Asymterric transport of a fluorescent glucose analogue by human erythrocytes. Biochimica et Biophysica Acta 815: 75-84.
38. Mallas G, Brooks DH, Rosenthal A, Nudelman RN, Mauskapf A, et al. (2012) Improving quantification of intravascular fluorescence imaging using structural information. Phys Med Biol 57: 6395-6406.